An overview of the impact and burden of Hepatitis C virus in the US, treatment landscape, elimination progress, access restrictions and the health economics of curative treatment.

This program will review:

• Disease state pathophysiology, burden, and impact of Hepatitis C in the US

• The WHO HCV elimination targets and the progress to date

• The current treatment landscape and the most recent AASLD/IDSA guideline recommendations for the treatment of HCV

• The current access of HCV treatments and the health economics of curative treatment

At the end of the program, attendees should be able to:

• Understand the pathophysiology and organ systems affected by Hepatitis C

• Recognize the burden and unmet medical needs for patients with HCV

• Discuss the current treatment guidelines for management of patients with HCV

• Understand the current access of HCV treatments and the health economics of curative treatment

Speakers:

• Nancy Reau, MD
  Professor, Department of Internal Medicine, Division of Digestive Diseases and Nutrition
  Section Chief of Hepatology & Associate Director of Organ Transplantation
  Rush University Medical Center

• Avani Joshi, BPharm., PhD
  Director, Medical Payer Strategy
  US Medical Affairs, Abbvie

This webinar is sponsored, developed, and presented by the sponsor.  The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP. Sponsored by: Abbvie